Skip to main content

Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine



The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio ‘end-game’ strategy.


We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26).


The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme.


The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.

Peer Review reports


Vaccines and associated pediatric immunization programs have been a vital public health intervention in reducing morbidity and mortality associated with many communicable diseases worldwide. These interventions not only protect those immunized, but also provide community-wide protection by reducing the spread of disease. In addition, the reduction in associated disease burden promotes healthy well-being which supports economic growth and poverty reduction [1, 2]. Improving vaccination coverage rates of pneumococcal, rotavirus, pertussis, measles, Haemophilus influenzae type b (Hib) and malaria (assuming their introduction in malaria-endemic countries) vaccines to 90% in seventy-two of the world’s poorest countries between 2011 and 2020 would save the lives of an estimated 6.4 million children aged < 5 years, representing $231 billion in the value of statistical lives saved [3].

Poliomyelitis is an acute paralytic disease caused by three poliovirus serotypes [4, 5]. The use of the formalin-inactivated Salk polio vaccine (IPV) (first introduced in 1955) and the Sabin oral polio vaccine (OPV) (introduced in the early 1960’s) in routine immunization programs and supplemental mass vaccination campaigns has led to the elimination or near elimination of poliomyelitis and polioviruses circulation from many countries [6]. Nonetheless, it is estimated that there are 10–20 million individuals worldwide living with poliomyelitis-related disabilities [7], though very little is known about the socio-economic consequences and healthcare costs of the disabilities.

OPV has been the vaccine of choice for the Global Polio Eradication Initiative (GPEI) of the World Health Organization (WHO) because of its low cost, ease of administration and superiority in inducing mucosal immunity [8, 9]. However, OPV vaccination carries some risks, namely the appearance of vaccine-associated paralytic poliomyelitis cases (VAPP) and the emergence of vaccine derived polioviruses (VDPV) [10]. The strategy for the elimination of all polioviruses, referred to as the polio endgame, includes two steps synchronized around the world for all countries still vaccinating with OPV. First the switch from trivalent OPV to bivalent OPV (as wild type OPV-2 no longer circulates), and second the switch from OPV to IPV in routine childhood immunization programs in order to avoid OPV-derived cases [10,11,12].

Vaccination against polio in Chile began in 1961 [13], and by 1975 the last case of wild polio was detected, 19 years before the South America region was declared polio-free [14]. As part of the Polio Eradication and Endgame Strategic Plan developed by the GPEI, the World Health Organization Strategic Advisory Group of Experts (WHO-SAGE) has recommended as a first step that all countries introduce at least one dose of IPV into their routine immunization programs [15], before the complete switch to immunization with IPV [16].

Combination vaccines have been developed and introduced in routine childhood immunization programs, allowing individuals to be simultaneously vaccinated against multiple infectious diseases including diphtheria, tetanus, pertussis, poliomyelitis, Hib and hepatitis B (HepB) [17, 18]. Combination vaccines have the additional advantages of increased vaccination coverage rates [19], improved vaccination timeliness, and reduction of the number injections required in an increasingly crowded immunization schedule [20,21,22].

Chile introduced a combined bivalent vaccine for diphtheria and pertussis (DP) into the routine childhood immunization program in 1950, which was later replaced by the trivalent vaccine that included pertussis (DTwP) in 1975. The tetravalent vaccine including Hib (DTwP-Hib) was introduced in 1996 and the switch to the pentavalent vaccine including HepB (DTwP-Hib-HepB) occurred in 2006. In 2015, Chile started to replace the 2-month OPV dose (used in combination with the pentavalent vaccine) with IPV in line with WHO-SAGE recommendations to support the polio eradication endgame strategy, with the vaccination series completed with OPV (used in combination with the pentavalent vaccine) administered at 4, 6 and 18 months. Then in February 2018, the hexavalent vaccine including IPV (DTaP-IPV-HepB-Hib) was introduced at 2 and 4 month and the vaccination series completed with the pentavalent (DTwP-Hib-HepB) vaccine and OPV both administered at 6 and 18 months [23]. More recently, in December 2018, the hexavalent (DTaP-IPV-HepB-Hib) vaccine was recommended to provide all four polio vaccine doses at 2, 4, 6 and 18 months [24].

In Latin America, there is an increasing role for economic evaluations in supporting evidence-based decision making. This has also applied to the assessment of new vaccines or immunization programs (see for example Glassman et al. 2016 [25], and the Pan-American Health Organization (PAHO) [26]). Most of these studies are based on cost-effectiveness and/or cost-utility analysis.

We undertook this study to assess the economic impact of moving from the Chilean vaccination scheme in 2016 to a new program based upon the use of a full hexavalent (DTaP-IPV-HepB-Hib) vaccine scheme at 2, 4, 6 and 18 month of age. Because the new scheme represents a replacement of antigens, for both OPV to IPV and wP to aP, without any significant difference in the efficacy of the switched antigens, we considered a cost-minimization analysis as the most appropriate economic evaluation methodology to utilize.


The objective of the current study was to describe and analyze the cost differences between switching from the current vaccination scheme to a new scheme, based on a fully-liquid ready-to-use hexavalent vaccine. We considered a full switch between schemes to the new hexavalent program comprising 4 doses (three primary and one ‘booster’ doses). The programs were analyzed from the societal perspective.

The study cohort (infants eligible for vaccination) was taken from national statistics produced by the Chilean government [27]. The vaccination scheme in 2016, which consists of 4 doses of wP-containing pentavalent vaccine (DTwP-Hib-HepB) plus 1 dose IPV and 3 doses OPV, was based on the program from the Ministry of Health [23, 28] and the new scheme was assumed to replicate the same vaccine antigen coverage including the use of a ‘booster’ dose at 18 months. Vaccination coverage rates were taken as the average of those achieved in Chile between 2006 and 2015 [29].

Adverse event rates, associated with vaccination, were taken from previously published studies [30, 31] and included: seizures (with or without fever) and hypotonia-hyporesponsiveness syndrome after wP vaccines, edema, vomiting, anorexia, pain and redness or irritation of the skin. Full details of the values used can be found in Table 1. For seizures and other neurological effects such as hypotonic-hyporesponsiveness, data were taken from two studies which estimated seizures (with or without fever) and hypotonia syndrome; hypotonic- hyporesponsiveness episodes after wP vaccines was estimated at 1 case/1750 vaccinated i.e. 0.57 cases/1000 doses [32] and 0.12 cases/1000 doses with the aP vaccines [31].

Table 1 Adverse event rates for vaccines containing whole-cell pertussis and acellular pertussis components [30]

It was assumed that some of the more serious adverse events result in costs being incurred, for example through medical consultations, absenteeism and medication. Those events which were deemed to result in medical treatment were severe injection site edema > 20 mm; severe pain; severe irritation due to agitation or persistent acute crying; and drowsiness. Based upon expert opinion, we assumed that 20% would be the appropriate consultation rate. For those suffering from some more serious neurological manifestations (e.g. convulsions with or without fever, hypotonia-hyporesponse syndrome) it was assumed that all cases consulted were hospitalized for 1.5 days, and had a single post-discharge outpatient consultation.

Cost data was taken from a variety of sources including PAHO, previous vaccine studies and national estimates and included: antipyretics use, patient transfers/travel expenses, medical consultation, hospitalization, lost work time/days for parental care, time to administer the vaccine dose [33], cost of vaccine distribution, cost of the cold chain, costs for programmatic errors, costs of OPV, IPV, hexavalent and pentavalent vaccines, cost for the purchase of the hexavalent vaccine in the private sector. Details of the costs included can be found in Table 2.

Table 2 Costs included

All costs are in 2017 prices. Prices were converted from Chilean pesos into US$ using an exchange rate of $Ch 666.26 = US$1 (April 2017) [38].

Four scenarios were modelled (Table 3); all were conducted from a social perspective. In Scenario 1, the cost of the scheme with hexavalent vaccine was estimated according to its reference price in the Revolving Fund of PAHO for 2017 and compared with the cost of the 2016 plan, which implies the expenditure of pentavalent vaccine (reference price of the bidding in place), plus spending on polio vaccine according to its average price in the Revolving Fund and the additional costs involved in the simultaneous scheme with the pentavalent vaccine. In this scenario, the price of the polio vaccine was the average of the prices of 1 dose of IPV and 3 doses of OPV.

Table 3 Summary of the switch from vaccination schemes based on the pentavalent vaccine with whole-cell pertussis component (wP) plus various combinations/presentations of IPV or OPV vaccines assessed in scenarios 1 to 4 to the hexavalent vaccine with acellular pertussis component (aP) and IPV

Scenario 2 compared the current pentavalent vaccination plan and an additional 4-dose full IPV scheme versus vaccinating with hexavalent vaccine. The cost of the program with hexavalent vaccine was estimated based on its reference price in the Revolving Fund of PAHO of 2017 and compared with the cost of the current plan modified with the inclusion of a 4-dose full IPV scheme, which includes expenditure on the pentavalent vaccine (reference price of the tender in place), plus the average price of IPV in the PAHO Revolving Fund for 2017 for a 4-dose full IPV scheme and the additional costs which assumes the simultaneous scheme with the pentavalent vaccine. In this scenario, the price of IPV was the average of the prices of two different vaccines presentations in the Revolving Fund since there is a real possibility that the distribution of this vaccine through the Revolving Fund may vary due to supply issues.

Scenario 3 was similar to Scenario 2 above, but used the lowest reported price for IPV (US$ 2.10) reported in the PAHO revolving fund. Scenario 4, was also based on Scenario 2 above, but used the highest reported price for IPV (US$ 5.10) reported in the PAHO revolving fund.


The population of Chile was found to be relatively stable in the period 2010–2017 (Table 4). We used the data from the last full recorded year (2016) with a cohort of children aged < 1 year (249,552) and aged under 2 years (249,221) in this analysis.

Table 4 Population of Chile (projection of the 2 cohorts, 2007–2017)

From a societal perspective, the costs associated with the management of adverse events with the 2016 vaccination scheme (4 doses pentavalent vaccine + 1 dose IPV and 3 doses OPV) are US$ 8.84 million (Table 5) and those for the current vaccines used, US$ 3.86 million (Table 6). Thus, the overall costs associated with 2016 vaccination scheme are US$ 12.70 million. In comparison, the costs associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) would be US$ 19.76 million (Table 6). Therefore, the cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million (Scenario 1). The results for the other three scenarios are also shown in Table 6. The costs of switching to the hexavalent scheme would range from additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme according to the scenario considered.

Table 5 Summary of the additional costs involved in the use of vaccines containing whole-cell pertussis component (societal perspective)
Table 6 Costs distribution according to scenario 1 to 4 from the societal perspective

The difference of 30,944 doses in the amount of hexavalent and the other vaccines is based on 7736 children in the private market receiving four doses of Hexavalent (3 + 1 scheme), and was assumed that the ministry of health would reimburse the vaccine for the whole cohort.

In Scenario 4, the switch to the hexavalent scheme would cost US$ 2.62 million.


In this study, we estimated and compared the difference in costs generated by two schemes with similar health outcomes but differences in the costs and safety, which were largely associated with logistics and adverse events management. The four scenarios analyzed considered two different approaches towards polio immunization, moving from a representation of Chile’s 2016 approach (1 dose of inactivated polio vaccine, followed by 3 doses of OPV) towards the GPEI objective in which OPV should be suspended as soon as possible, which means that the complete IPV scheme (i.e. all doses used are IPV) would become the preferred option. Several countries in Latin America have already expressed interest in a complete IPV scheme, similar to that introduced in Uruguay in 2012, but the supply of IPV has not been adequate or sufficiently reliable to fully comply with that policy. Based upon the PAHO reference prices, use of the hexavalent vaccine implies a greater expense versus simultaneous vaccination using the current pentavalent plus polio vaccines. However, the existence of more adverse events in the current scheme associated with wP compared to the aP formulation of the hexavalent scheme minimizes the cost difference between the two schemes.

There have been relatively few published assessments of the economic impact of hexavalent vaccines. A study in France (where the hepatitis B vaccine coverage was low) of a hexavalent combination vaccine, found that the public price associated with a break-even point would be €53.77. The annual additional reimbursed cost of protecting an infant against the risk of hepatitis B was €28.20 per child, or about €21 million for an annual cohort of 760,000 births (total cost, €35 million) [39]. Whilst there are problems with direct comparisons between France and Chile, due to differences in the healthcare systems and relative GDP of the two countries, the use of a hexavalent vaccine in our hypothetical model does produce similar increase in overall costs when factoring in the lower population covered in Chile.

Our findings are supported by a previous study conducted in Latin America. An earlier study in Mexico examined the impact of moving from OPV to IPV vaccination schedule. The authors found that changing from the existing OPV-based routine schedule and intensive supplementary activities to a sequential IPV-OPV routine schedule using a pentavalent and IPV/OPV vaccines would save US$ 14.52 per vaccinated child, and changing to a full IPV routine schedule would save US$ 9.41 per vaccinated child [40]. This latter figure is consistent with the outcomes reported in Scenario 4 of our analysis using the lower price for the hexavalent vaccine.

A similar cost-minimization analysis has been performed for hexavalent vaccine introduction in South Africa, which analyzed replacing aP pentavalent vaccine and Hep B by the hexavalent combination. The authors concluded that implementing a hexavalent vaccine in South Africa was highly recommended, because it reduces healthcare provider costs by simplifying logistics and delivery infrastructure: reduced clinic visits, vaccination errors, number of injections and side effects, which can be expected to translate to better acceptability, convenience and increased compliance [41].

The strengths of our analysis are that we utilized nationally available data, or taken from peer-reviewed scientific publications. Our analysis also produced results which are consistent with other previous analyses reported. One of the possible weaknesses of our analysis is that it relies on the assumption that the hexavalent vaccine has similar efficacy to the currently used vaccines. If this assumption were subsequently shown to be inaccurate, then the approach we took here (cost-minimization) would no longer be appropriate.

Contradictory evidence exists on the aP vs. wP benefits. On one side, concerns about the immunity conferred by aP vaccines not being as complete or as long lasting as that with wP vaccines [42], and it is also possible that the immunity elicited by wP vaccines may better protects against colonization and transmission than that elicited by aP vaccines [43, 44]. On the other side, some studies documented that the switch to aP vaccines reduced all-cause hospitalization in infants [45], and that this would expected to reduce global costs.

Our analysis may have underestimated the benefits of switching to a new hexavalent scheme since the reduction in immunizations required, might well be valued by the parents involved, leading to increased coverage and/or improved timeliness of infants immunization, which isn’t captured in our analysis [19,20,21,22].


The introduction of a hexavalent (DTaP-IPV-HepB-Hib) vaccine into the immunization schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the 2016 vaccines. This analysis provides decision makers with additional information on the potential impact of changes to the vaccination schedule caused by technical innovations, whilst reflecting the likely supply of alternative vaccines.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].



Acellular pertussis vaccine component


Diphtheria and pertussis


Diphtheria, tetanus and pertussis


Global Polio Endgame Initiative


Hepatitis B vaccine component


Haemophilus influenzae type b


Inactivated polio vaccine


Oral polio vaccine


Pan American Health Organization


Whole-cell pertussis vaccine component


World Health Organization, Strategic Advisory Group of Experts


  1. 1.

    Bloom DE. The value of vaccination. Adv Exp Med Biol. 2011;697:1–8.

    Article  Google Scholar 

  2. 2.

    Barnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, et al. Reassessing the value of vaccines. Lancet Glob Health. 2014;2(5):e251–2.

    Article  Google Scholar 

  3. 3.

    Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, Walker DG, Levine OS. During the 'decade of vaccines,’ the lives of 6.4 million children valued at $231 billion could be saved. Health Aff (Millwood). 2011;30(6):1010–20.

    Article  Google Scholar 

  4. 4.

    World Health Organization: Poliomyelitis. 2019. Accessed 23 March 2020.

  5. 5.

    Centers for Disease Control and Prevention. Poliomyelitis In Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed: The Pink Book; 2015. Accessed 23 March 2020.

  6. 6.

    Greene SA, Ahmed J, Datta SD, Burns CC, Quddus A, Vertefeuille JF, Wassilak SGF. Progress toward polio eradication - worldwide, January 2017-March 2019. MMWR Morb Mortal Wkly Rep. 2019;68(20):458–62.

  7. 7.

    Nielsen NM, Kay L, Wanscher B, Ibsen R, Kjellberg J, Jennum P. Long-term socio-economic consequences and health care costs of poliomyelitis: a historical cohort study involving 3606 polio patients. J Neurol. 2016;263(6):1120–8.

    Article  Google Scholar 

  8. 8.

    World Health Organization. Polio vaccines and routine polio immunization in the preeradication era. 2010. Accessed 23 March 2020.

  9. 9.

    World Health Organization. Polio vaccines position paper. 2016. Accessed 23 March 2020.

  10. 10.

    Lopalco PL. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect. 2017;145(3):413–9.

    CAS  Article  Google Scholar 

  11. 11.

    Sutter RW, Platt L, Mach O, Jafari H, Aylward RB. The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014;210(Suppl 1):S434–8.

    Article  Google Scholar 

  12. 12.

    Pallansch MA. Ending use of Oral poliovirus vaccine - a difficult move in the polio endgame. N Engl J Med. 2018;379(9):801–3.

    Article  Google Scholar 

  13. 13.

    Communicable Disease Center. Poliomyelitis surveillance. 1962. Accessed 23 March 2020.

  14. 14.

    Ministerio de Salud Chile. Poliomielitis. 2015. Accessed 23 March 2020.

  15. 15.

    Global Polio Eradication Initiative. Introduction of inactivated polio vaccine (IPV) in routine immunizations. 2014. Accessed 23 March 2020.

  16. 16.

    World Health Organization. The Polio Endgame Strategy 2019-2023: Eradication, Integration, Containment and Certification. 2019. Accessed 23 March 2020.

  17. 17.

    Nunes MC, Madhi SA. Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Ther. 2013;13(4):575–93.

    CAS  Article  Google Scholar 

  18. 18.

    Maman K, Zollner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132–41.

    Article  Google Scholar 

  19. 19.

    Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496–500.

    Article  Google Scholar 

  20. 20.

    Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–12.

    Article  Google Scholar 

  21. 21.

    Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 Suppl):S6–12.

    PubMed  Google Scholar 

  22. 22.

    Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care. 2008;22(5):300–9.

    Article  Google Scholar 

  23. 23.

    Ministerio de Salud deChile. Calendario de vacunación. 2018. Accessed 7 January 2019.

    Google Scholar 

  24. 24.

    Ministerio de Salud deChile. Calendario de Vacunación 2019. 2019. Accessed 7 January 2019.

    Google Scholar 

  25. 25.

    Glassman A, Canon O, Silverman R. How to get cost-effectiveness analysis right? The case of vaccine economics in Latin America. Value Health. 2016;19(8):913–20.

    Article  Google Scholar 

  26. 26.

    Pan American Health Organization. Promotion of evidence-based decision making for the introduction of new vaccines. 2018. Accessed 23 March 2020.

  27. 27.

    Instituto Nacional de Estadísticas ChiIe. Proyecciones de población. Proyección de población 2002-2020. 2017. Accessed 12 May 2017.

  28. 28.

    Ministerio de Salud de Chile. Programa Nacional de Inmunizaciones. 2017. Accessed 22 May 2017.

    Google Scholar 

  29. 29.

    World Health Organization. WHO/UNICEF coverage estimates for 1980–2015, as of 15 July 2016. 2016. Accessed 23 March 2020.

  30. 30.

    Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, Anderson EL, Deloria MA, Reed GF. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96(3 Pt 2):557–66.

    CAS  PubMed  Google Scholar 

  31. 31.

    Centres for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-7):1–25.

    Google Scholar 

  32. 32.

    Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68(5):650–60.

    CAS  PubMed  Google Scholar 

  33. 33.

    De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B, Van Damme P. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976–82.

    Article  Google Scholar 

  34. 34.

    Arancel MAI. MINSAL Chile. In: Comprehensive medical consultation, Medium Complexity Hospital, Equivalent Emergency Service; 2018.

    Google Scholar 

  35. 35.

    Arancel MAI. MINSAL Chile. In: Hospitalization in Pediatric Intensive Care. 1.5 days, considering bed day price plus average attention involved (extrapolated from an influenza study); 2018.

    Google Scholar 

  36. 36.

    CENABAST. Central supply of the National System of health services (CENABAST). Chile: Ministry of Health; 2018.

    Google Scholar 

  37. 37.

    Pan American Health Organization. Revolving fund prices. 2017. Accessed 20 April 2017.

  38. 38.

    Banco Central de Chile. Paridades y Tipos de cambio. 2017. Accessed 23 March 2020.

  39. 39.

    Fagnani F, Le Fur C, Durand I, Gibergy M. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule. Eur J Health Econ. 2004;5(2):143–9.

    Article  Google Scholar 

  40. 40.

    Mascareñas A, Salinas J, Tasset-Tisseau A, Mascarenas C, Khan MM. Polio immunization policy in Mexico: economic assessment of current practice and future alternatives. Public Health. 2005;119(6):542–9.

  41. 41.

    Mogale K, Burnett RJ, Olivier D, Mphahlele J. Economic assessment of implementing Hexaxim® vaccine within the south African expanded Programme on immunisation (EPI-SA). Int J Infect Dis. 2014;21S:430.

    Article  Google Scholar 

  42. 42.

    Jackson DW, Rohani P. Perplexities of pertussis: recent global epidemiological trends and their potential causes. Epidemiol Infect. 2014;142(4):672–84.

    CAS  Article  Google Scholar 

  43. 43.

    Smallridge WE, Rolin OY, Jacobs NT, Harvill ET. Different effects of whole-cell and acellular vaccines on Bordetella transmission. J Infect Dis. 2014;209(12):1981–8.

    CAS  Article  Google Scholar 

  44. 44.

    Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111(2):787–92.

    CAS  Article  Google Scholar 

  45. 45.

    Desai S, Schanzer DL, Silva A, Rotondo J, Squires SG. Trends in Canadian infant pertussis hospitalizations in the pre- and post-acellular vaccine era, 1981-2016. Vaccine. 2018;36(49):7568–73.

    Article  Google Scholar 

Download references


We would like to thank Richard Glover and Keith Evans, of Springer Healthcare Communications for editorial assistance with the preparation of this manuscript. This assistance was funded by Sanofi Pasteur.


This research was funded by Sanofi Pasteur.

Author information




IO, HD, FPA and JGLY contributed to the conceptual design of the study and methodology. IO, HD, JGLY, CG, JPT, GM and LL participated in data collection, data analysis and interpretation of data generated. FPA performed a critical review of the overall project. All authors contributed to the critical revision of the article and final approval of the version to be published.

Corresponding author

Correspondence to Juan Guillermo López Yescas.

Ethics declarations

Ethics approval and consent to participate

Not applicable; study did not involve human participants.

Consent for publication

All author approved the version to be published.

Competing interests

HD, FPA and JGLY are employees of Sanofi. The authors declare that they have no other competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Olivera, I., Grau, C., Dibarboure, H. et al. Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine. BMC Health Serv Res 20, 295 (2020).

Download citation


  • Vaccination
  • Cost
  • Pediatric
  • Polio